Stage II EGFR Lung Cancer: Samantha's Patient Story

Patient Info: Samantha Vaughn, Female | Stage II

Biomarkers: EGFR mutation

Samantha had Stage II EGFR-mutated lung cancer removed surgically and was receiving post-operative daily Tagrisso through a clinical trial. As of June 2025, she reported clear results so far but remained on active targeted therapy.

The Patient StoryRead more →

Stage IV EGFR Lung Cancer: Natasha's Patient Story

Patient Info: Natasha, Female | Stage IV

Biomarkers: EGFR-positive

Metastatic Site: brain

Natasha had Stage IV EGFR-positive lung cancer with brain metastases. Tagrisso/osimertinib was her main treatment, but a new brain metastasis later appeared and was treated with Gamma Knife. As of May 2025, she was awaiting follow-up MRI while continuing care.

The Patient StoryRead more →

How We Got Here: 6 Young Lung Cancer Patients & Their Paths To Surgery- Part 1

Patient Info: Leah Phillips, Female | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: bone (pelvis; spine; ribs)

As of April 2025, Leah was living with Stage IV EGFR exon 19 deletion lung cancer while continuing Tagrisso after SBRT and right middle lobe lobectomy.

YouTube (JA search)Read more →

EGFR-Mutant Lung Adenocarcinoma That Transformed to Small Cell Lung Cancer

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: liver

The cancer progressed after transformation to small cell lung cancer, and she died 49 months after the original diagnosis.

PubMed CentralRead more →

EGFR-Mutant Lung Adenocarcinoma That Transformed to Small Cell Lung Cancer

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain, adrenal gland, liver, thyroid

The cancer progressed after small-cell transformation with adrenal, thyroid, liver and brain involvement, and she died 52.7 months after the original diagnosis from disease progression and organ failure.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Jeff's Patient Story

Patient Info: Jeff, Male, 60s | Stage IV

Biomarkers: EGFR-positive; exon 19 mentioned

Metastatic Site: brain; bones — ribs, femur/hip, clavicle

Jeff has Stage IV EGFR-positive non-small cell lung cancer with brain and bone metastases. Biomarker testing changed the plan from radiation/chemotherapy toward Tagrisso targeted therapy. As of March 2025, he was living with metastatic lung cancer and emphasizing hope and self-advocacy.

The Patient StoryRead more →

EGFR-Mutant Lung Cancer With Pleomorphic Transformation Treated With Local Surgery

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR L858R mutation; PD-L1 less than 1% initially and greater than 75% after transformation

Metastatic Site: brain

Nine months after surgery for isolated progression, no recurrence had been seen and she remained on osimertinib.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Leah's Patient Story

Patient Info: Leah Phillips, Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Not reported

As of December 2024, Leah was recovering well a few weeks after right-middle-lobe lobectomy, but remained a Stage IV EGFR-mutated lung cancer patient needing ongoing treatment and follow-up.

MD AndersonRead more →

Metastatic EGFR-positive lung adenocarcinoma: osimertinib cardiomyopathy managed with SGLT2 inhibitor support

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR-positive; specific EGFR sequence variant not reported in extracted case text

As of December 2024, he remained clinically stable and asymptomatic 12 months after osimertinib rechallenge with empagliflozin, losartan, metoprolol, and close cardiac monitoring; the extracted case focuses on cardiotoxicity management rather than tumor response.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Filipe's Patient Story

Patient Info: Filipe, Male, Under 40 | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain, bone, left lung, kidney

As of November 2024, Filipe was living with ongoing Stage IV EGFR exon 19-mutated lung cancer after initial response to osimertinib, later progression and current amivantamab plus chemotherapy.

The Patient StoryRead more →

Stage III EGFR exon 19-deleted lung adenocarcinoma: osimertinib and surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion

No sign of metastasis on PET-CT or brain MRI after 24 months of follow-up following neoadjuvant osimertinib, left upper-lobe resection, and adjuvant osimertinib.

PubMed CentralRead more →

Stage I Lung Adenocarcinoma With Later Kidney Metastases Responding to Osimertinib

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; RB1 mutation; MAP3K1 mutation; PD-L1 negative

Metastatic Site: kidneys, peritoneal lymph nodes

Osimertinib produced a partial response within 6 weeks after metastatic recurrence in the kidneys. She remained alive and continued targeted treatment.

PubMed CentralRead more →

EGFR exon 19 deletion lung cancer: gefitinib after osimertinib toxicity

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion

As of August 2024, Stage IVB EGFR exon 19 deletion lung adenocarcinoma was being treated with gefitinib after osimertinib-induced grade 3 interstitial lung disease; ILD had not recurred, and low-dose prednisolone continued.

PubMed CentralRead more →

Stage 4 EGFR-mutant lung cancer controlled on gefitinib after osimertinib intolerance

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: EGFR exon 21 L858R mutation

As of August 2024, Stage IVB EGFR L858R lung adenocarcinoma was being treated with gefitinib after grade 3 osimertinib-induced interstitial lung disease; the cancer had not progressed when steroids were completed and ILD had not recurred on gefitinib.

PubMed CentralRead more →

EGFR-mutant lung adenocarcinoma transforming to small cell lung cancer during targeted therapy

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion, TP53 mutation, TMB 11 mut/Mb

Metastatic Site: cervical lymph nodes

At the last follow-up in February 2024, 32 months after diagnosis, she was alive and both the primary lung lesion and cervical lymph-node metastasis had decreased on combined chemotherapy, immunotherapy and targeted therapy.

PubMed CentralRead more →

Seven-year response journey in EGFR-mutated metastatic lung adenocarcinoma

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: pleura, brain

About 7 years after presentation with metastatic lung adenocarcinoma, he remained on targeted therapy. Gefitinib controlled the disease for 5 years; after brain progression, osimertinib followed by stereotactic radiation produced a complete intracranial response.

PubMed CentralRead more →

Stage IIIA EGFR-mutated lung adenocarcinoma: surgery after osimertinib

Patient Info: Anonymized, Male, 60s

Biomarkers: EGFR E746_A750 deletion; PD-L1 TPS 15%; TMB 5.01 Muts/Mb; TTF-1 3+; CK7 3+; Ki67 60%

As of July 2024, surveillance CT scans at 2, 6, and 12 months after surgery showed no recurrent malignancy while he continued adjuvant osimertinib.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Leah's Patient Story

Patient Info: Leah Phillips, Female, 40s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: bone (spine, pelvis); malignant right pleural…

As of July 2024, Leah remained on daily Tagrisso with stable Stage IV EGFR-mutated lung cancer, no reported progression, healing/sclerotic bone metastases, and durable response for more than 4 years.

The Patient StoryRead more →

Near-complete response to osimertinib in Stage IV lung adenocarcinoma with rare EGFR mutations

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: EGFR S768I mutation, PD-L1 TPS 2%

Metastatic Site: pleura, bone, lymph nodes

After progression on vinorelbine and carboplatin, osimertinib produced a metabolic complete response by December 2023 and a near-complete radiologic response in March 2024. He remained on osimertinib with good tolerance and stable clinical condition.

PubMed CentralRead more →

Stage 3 EGFR-mutant lung cancer: osimertinib response to surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion; PD-L1 tumor proportion score <=1%

No recurrence or metastasis was reported after neoadjuvant osimertinib, R0 left upper lobectomy with mediastinal lymphadenectomy, and ongoing adjuvant osimertinib for Stage IIIA EGFR exon 19 deletion lung adenocarcinoma.

PubMed CentralRead more →

EGFR-mutated lung cancer treated with osimertinib during tuberculosis therapy

Patient Info: Anonymized, female, 70+ | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, left axillary lymph node

Osimertinib maintained a partial response throughout 9 months of tuberculosis treatment, with no new abdominal or brain lesions. By the end of tuberculosis treatment, she was more than 7 years from her original lung-cancer diagnosis.

PubMed CentralRead more →

EGFR-mutated lung cancer with later small-cell transformation

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: EGFR L858R mutation; acquired EGFR T790M mutation

Metastatic Site: pleura/chest wall, ribs, brain, meninges,…

Disease progressed through multiple lines of therapy with brain and meningeal involvement. He died in September 2021, more than 9 years after his original 2012 diagnosis.

PubMed CentralRead more →

Stage II EGFR Non-Small Cell Lung Cancer: Daniel's Survivor Story

Patient Info: Daniel West, Male | Stage II

Biomarkers: EGFR alteration

At the latest report, Daniel had no evidence of active cancer; small lung nodules were being monitored without progression while he continued osimertinib.

Jeff

Patient Info: Jeff, Male | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain|bones|lymph nodes

The lung mass shrank, 5 brain lesions and the involved lymph node had no evidence of disease, and Jeff described his condition as stable while continuing osimertinib and bone-strengthening infusions.

Lung Cancer Research FoundationRead more →